Analysts Set Haemonetics Corporation (NYSE:HAE) Target Price at $84.10

Haemonetics Corporation (NYSE:HAE) has earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $84.10.

HAE has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a report on Friday, December 12th. Wall Street Zen lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Sunday, December 14th. Mizuho raised their price objective on shares of Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Raymond James Financial reissued an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Finally, Needham & Company LLC lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th.

Hedge Funds Weigh In On Haemonetics

Several institutional investors and hedge funds have recently bought and sold shares of HAE. FNY Investment Advisers LLC purchased a new stake in shares of Haemonetics in the third quarter worth approximately $233,000. CIBC Private Wealth Group LLC grew its position in Haemonetics by 69.3% during the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 448 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new position in Haemonetics in the 3rd quarter valued at approximately $251,000. Danske Bank A S acquired a new stake in shares of Haemonetics during the 3rd quarter valued at $665,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Haemonetics by 20,925.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 837 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

NYSE HAE opened at $80.00 on Wednesday. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The business’s fifty day moving average is $74.40 and its two-hundred day moving average is $65.54. The stock has a market capitalization of $3.74 billion, a P/E ratio of 23.39, a P/E/G ratio of 1.51 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The company’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.